Strs Ohio Has $613,000 Position in Dynavax Technologies Corporation $DVAX

Strs Ohio lifted its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX) by 196.6% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 61,700 shares of the biopharmaceutical company’s stock after buying an additional 40,900 shares during the period. Strs Ohio’s holdings in Dynavax Technologies were worth $613,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Osaic Holdings Inc. grew its stake in Dynavax Technologies by 15.1% during the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 1,226 shares during the period. Callan Family Office LLC bought a new position in shares of Dynavax Technologies during the 2nd quarter worth approximately $107,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Dynavax Technologies during the 2nd quarter worth approximately $121,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Dynavax Technologies during the 3rd quarter worth approximately $122,000. Finally, Pinnacle Wealth Planning Services Inc. acquired a new position in shares of Dynavax Technologies during the 2nd quarter valued at $127,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

Shares of NASDAQ DVAX opened at $15.48 on Friday. The stock has a market capitalization of $1.82 billion, a P/E ratio of -41.84 and a beta of 0.89. The company has a 50-day moving average price of $13.44 and a 200-day moving average price of $11.46. Dynavax Technologies Corporation has a 1 year low of $9.20 and a 1 year high of $15.73. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. The company had revenue of $94.88 million for the quarter, compared to analyst estimates of $94.00 million. On average, equities research analysts forecast that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Insider Activity at Dynavax Technologies

In other news, COO David F. Novack sold 114,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $15.64, for a total value of $1,782,960.00. Following the transaction, the chief operating officer owned 63,344 shares in the company, valued at $990,700.16. This trade represents a 64.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.98% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

DVAX has been the subject of a number of research reports. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, January 21st. Wall Street Zen raised shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 27th. Finally, William Blair lowered Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Dynavax Technologies has a consensus rating of “Hold” and a consensus price target of $24.33.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.